Summary
Axon Enterprise, Inc. (AXON) has announced its entry into privately negotiated Exchange Agreements with certain holders of its 0.50% convertible senior notes due 2027. These agreements will facilitate the exchange of approximately $177.9 million in aggregate principal amount of these notes for a combination of cash and newly issued Axon common stock. The exact number of shares to be issued will be determined based on a one-day volume-weighted average price (VWAP) on December 10, 2025, with an estimated issuance of 468,000 shares assuming a hypothetical VWAP of $550.95. This transaction is expected to reduce the outstanding principal amount of the convertible notes to approximately $100.1 million upon closing, anticipated around December 16, 2025. The company is utilizing an exemption under Section 4(a)(2) of the Securities Act for the issuance of these shares, requiring holders to be accredited and qualified institutional buyers. Investors should note that the unwinding of hedging positions by some noteholders could potentially lead to increased volatility in Axon's stock price around the closing date.
Key Highlights
- 1Axon is exchanging approximately $177.9 million of its 0.50% convertible senior notes due 2027 for cash and common stock.
- 2The exchange is expected to reduce the outstanding principal of these notes to roughly $100.1 million.
- 3Approximately 468,000 shares of common stock are anticipated to be issued, based on a projected $550.95 per share average price.
- 4The issuance of shares is being conducted under an exemption from registration requirements (Section 4(a)(2) of the Securities Act).
- 5Holders participating in the exchange are required to be accredited and qualified institutional buyers.
- 6Unwinding of hedging strategies by some noteholders could significantly impact Axon's stock price around the closing date.
- 7The closing of these exchanges is expected to occur on or about December 16, 2025.